{
    "organizations": [],
    "uuid": "44afbe4bae4380e921bb10749241aea0aa353cb5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-gsk-receives-fda-approval-for-expa/brief-gsk-receives-fda-approval-for-expanded-indication-for-fluarix-idUSASB0C0TE",
    "ord_in_thread": 0,
    "title": "BRIEF-GSK Receives FDA Approval For Expanded Indication For Fluarix",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 12 (Reuters) - Glaxosmithkline Plc:\n* GSK RECEIVES FDA APPROVAL FOR EXPANDED INDICATION FOR FLUARIXÂ® QUADRIVALENT (INFLUENZA VACCINE) FOR PERSONS 6 MONTHS AND OLDER Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-12T21:06:00.000+02:00",
    "crawled": "2018-01-13T14:42:34.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "glaxosmithkline",
        "plc",
        "gsk",
        "receives",
        "fda",
        "approval",
        "expanded",
        "indication",
        "quadrivalent",
        "influenza",
        "vaccine",
        "person",
        "month",
        "older",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}